Exploiting Mouse Models to Recapitulate Clinical Tumor Dormancy and Recurrence in Breast Cancer
- PMID: 35560214
- DOI: 10.1210/endocr/bqac055
Exploiting Mouse Models to Recapitulate Clinical Tumor Dormancy and Recurrence in Breast Cancer
Abstract
Breast cancer recurrence and metastasis from activated dormant tumors remain the leading causes in disease morbidity. Women with estrogen receptor-positive breast cancer that accounts for nearly 80% of all cases face a lifelong risk of relapse after initial treatment. The biology of dormant tumors and dormant cancer cells that give rise to recurrent disease and metastasis remain to be understood for us to overcome the clinical challenges that they bring. The selection and optimization of preclinical models to recapitulate dormancy and recurrence in patients is critical for studying the underlying cellular and environmental factors. Here, we provide a brief review of studies that utilize mouse models to dissect the mechanisms of dormancy and therapeutic strategies to avert recurrence. This review specifically accentuates the versatility and benefits of immunocompetent transgenic mouse models that can be manipulated to recapitulate primary dormancy, metastatic dormancy, and post-therapy dormancy.
Keywords: breast cancer; recurrence; transgenic mouse model; tumor dormancy.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Cellular dormancy in minimal residual disease following targeted therapy.Breast Cancer Res. 2021 Jun 4;23(1):63. doi: 10.1186/s13058-021-01416-9. Breast Cancer Res. 2021. PMID: 34088357 Free PMC article.
-
Natural Killer Cell Regulation of Breast Cancer Stem Cells Mediates Metastatic Dormancy.Cancer Res. 2024 Oct 15;84(20):3337-3353. doi: 10.1158/0008-5472.CAN-24-0030. Cancer Res. 2024. PMID: 39106452 Free PMC article.
-
Metastasis dormancy in estrogen receptor-positive breast cancer.Clin Cancer Res. 2013 Dec 1;19(23):6389-97. doi: 10.1158/1078-0432.CCR-13-0838. Clin Cancer Res. 2013. PMID: 24298069 Free PMC article. Review.
-
Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy.J Clin Invest. 2015 Jun;125(6):2484-96. doi: 10.1172/JCI74883. Epub 2015 May 11. J Clin Invest. 2015. PMID: 25961456 Free PMC article.
-
Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis.Breast Dis. 2006-2007;26:87-98. doi: 10.3233/bd-2007-26108. Breast Dis. 2006. PMID: 17473368 Review.
Cited by
-
Exercise as cancer treatment: A clinical oncology framework for exercise oncology research.Front Oncol. 2022 Sep 2;12:957135. doi: 10.3389/fonc.2022.957135. eCollection 2022. Front Oncol. 2022. PMID: 36119508 Free PMC article.
-
Osteopontin is a therapeutic target that drives breast cancer recurrence.Nat Commun. 2024 Oct 24;15(1):9174. doi: 10.1038/s41467-024-53023-9. Nat Commun. 2024. PMID: 39448577 Free PMC article.
-
Advancements in Understanding the Hide-and-Seek Strategy of Hibernating Breast Cancer Cells and Their Implications in Oncology from a Broader Perspective: A Comprehensive Overview.Curr Issues Mol Biol. 2024 Aug 1;46(8):8340-8367. doi: 10.3390/cimb46080492. Curr Issues Mol Biol. 2024. PMID: 39194709 Free PMC article. Review.
-
A 31-plex panel for high-dimensional single-cell analysis of murine preclinical models of solid tumors by imaging mass cytometry.Front Immunol. 2023 Jan 19;13:1011617. doi: 10.3389/fimmu.2022.1011617. eCollection 2022. Front Immunol. 2023. PMID: 36741363 Free PMC article.
-
Dormancy of cutaneous melanoma.Cancer Cell Int. 2024 Feb 28;24(1):88. doi: 10.1186/s12935-024-03278-5. Cancer Cell Int. 2024. PMID: 38419052 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases